Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial

著者: Bruno François, Simon Lambden, Tom Fivez, Sébastien Gibot, Marc Derive, Jean‐Marie Grouin, Margarita Salcedo‐Magguilli, Jérémie Lemarie, Nicolas De Schryver, Ville Jalkanen, Tarik Hicheur, Jean–Jacques Garaud, Valérie Cuvier, Ricard Ferrer, Morten H. Bestle, Ville Pettilä, Jean‐Paul Mira, Camille Bouisse, Emmanuelle Mercier, Joris Vermassen, Vincent Huberlant, Isabelle Vinatier, Nadia Anguel, Mitchell M. Levy, Pierre‐François Laterre, Pierre Asfar, Mai-Anh Nay, Christophe Guitton, Jean‐Pierre Quenot, David Tran-Van, Julien Bohé, Gaëtan Plantefève, Saadalla Nseir, Jean‐Yves Lefrant, Xavier Monnet, Laurent Papazian, Christophe Vinsonneau, Jean‐Michel Constantin, Alexandre Mebazaa, Haikel Oueslati, D. Escudero, Fernando Martínez‐Sagasti, Enrique Piacentini, Paula Ramirez Galleymore, Thierry Dugernier, David Fagnoul, Isabelle Michaux, Allan Seibert, Matti Reinikainen, Thorbjørn Grøfte, Ignacio Martín‐Loeches, John G. Laffey - The Lancet 2023 被引用: 74